Quotient

Quotient P/B

Delisted

The P/B (Price-to-Book Ratio) of Quotient (QTNT) as of Nov 9, 2026 is -0.20. In the previous year, P/B (Price-to-Book Ratio) was -0.97 — a change of -79.85% (higher).

P/B

-0.20

YoY

-79.85%

Last updated:

P/B (Price-to-Book Ratio) of Quotient is 2022 -0.20 . P/B (Price-to-Book Ratio) of Quotient was 2021 -0.97 . It decreases by -79.85% higher compared to the previous year.

The Quotient P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2015
-17.42 USD
Jan 1, 2016
0.60 USD
Jan 1, 2017
-1.17 USD
Jan 1, 2018
-1.92 USD
Jan 1, 2019
16.41 USD
Jan 1, 2020
-5.09 USD
Jan 1, 2021
-0.97 USD
Jan 1, 2022
-0.20 USD
The Quotient P/B history
YEARP/BYoY
-0.20-79.85%
-0.97-80.97%
-5.09-131.01%
16.41-953.62%
-1.92+64.66%
-1.17-293.94%
0.60-103.46%
-17.42+1,852.69%
-0.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quotient Stock analysis

What does Quotient do? Quotient Ltd is a biopharmaceutical company headquartered in Eysins, Switzerland. The company was founded in 2007 with the aim of developing innovative technologies in the field of Personalized Medicine. This means that medications and therapies are specifically tailored to the individual needs of patients. Thanks to state-of-the-art production processes, products can be produced quickly and safely. Quotient Ltd has a unique business model based on transfusion technology. This technology allows the company to produce medications quickly and accurately. The different components of the medications are separated and then combined in the required dosage. This means that the medications can be precisely dosed and the risks of side effects minimized. A key focus of Quotient Ltd is the development of therapeutics. Personalized medicine and the fast and safe production of medications are at the center of this area. The transfusion technology enables medications to be produced quickly and flexibly, which is particularly important for rare diseases and personalized therapies. Another important area is the development of diagnostics. These enable diseases to be diagnosed quickly and safely. Based on this diagnosis, suitable therapies are then developed. Quotient Ltd also relies on transfusion technology for this, which enables fast, reliable, and flexible production of diagnostics. In addition to its developed technology and know-how, Quotient Ltd also has its own production facility. Here, all products are produced to the highest standards. The production facility covers an area of approximately 6,000 square meters. The modern facility is equipped with the latest technologies and meets the highest quality standards. Quotient Ltd offers a variety of products, with a special focus on personalized medicine and the fast and safe production of medications and diagnostics. One example is the PDA diagnostic system, which was developed for the fast and accurate diagnosis of autoimmune diseases. The MosaiQ system is another important product that enables fast and reliable production of medications. The success story of Quotient Ltd is closely linked to the development of transfusion technology. The company has succeeded in developing a technology that allows for the fast and safe production of personalized medicine. This technology has made Quotient Ltd a leading company in the field of personalized medicine worldwide. Today, Quotient Ltd employs over 700 people who are constantly working on the further development of personalized medicine and transfusion technology. Quotient is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quotient stock

P/B (Price-to-Book Ratio) of Quotient is -0.20 in 2022.

P/B (Price-to-Book Ratio) of Quotient changed from -0.97 to -0.20, representing a -79.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Quotient since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Quotient with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Quotient

All Key Metrics — Quotient